New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine : progress and challenges
© The Author(s) 2024. Published by Oxford University Press..
Despite a standardized diagnostic examination, cancer of unknown primary (CUP) is a rare metastatic malignancy with an unidentified tissue of origin (TOO). Patients diagnosed with CUP are typically treated with empiric chemotherapy, although their prognosis is worse than those with metastatic cancer of a known origin. TOO identification of CUP has been employed in precision medicine, and subsequent site-specific therapy is clinically helpful. For example, molecular profiling, including genomic profiling, gene expression profiling, epigenetics and proteins, has facilitated TOO identification. Moreover, machine learning has improved identification accuracy, and non-invasive methods, such as liquid biopsy and image omics, are gaining momentum. However, the heterogeneity in prediction accuracy, sample requirements and technical fundamentals among the various techniques is noteworthy. Accordingly, we systematically reviewed the development and limitations of novel TOO identification methods, compared their pros and cons and assessed their potential clinical usefulness. Our study may help patients shift from empirical to customized care and improve their prognoses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Briefings in bioinformatics - 25(2024), 2 vom: 22. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Wenyuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer of unknown primary (CUP) |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/bib/bbae028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368334775 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368334775 | ||
| 003 | DE-627 | ||
| 005 | 20240214233345.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/bib/bbae028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368334775 | ||
| 035 | |a (NLM)38343328 | ||
| 035 | |a (PII)bbae028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Wenyuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine |b progress and challenges |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press. | ||
| 520 | |a Despite a standardized diagnostic examination, cancer of unknown primary (CUP) is a rare metastatic malignancy with an unidentified tissue of origin (TOO). Patients diagnosed with CUP are typically treated with empiric chemotherapy, although their prognosis is worse than those with metastatic cancer of a known origin. TOO identification of CUP has been employed in precision medicine, and subsequent site-specific therapy is clinically helpful. For example, molecular profiling, including genomic profiling, gene expression profiling, epigenetics and proteins, has facilitated TOO identification. Moreover, machine learning has improved identification accuracy, and non-invasive methods, such as liquid biopsy and image omics, are gaining momentum. However, the heterogeneity in prediction accuracy, sample requirements and technical fundamentals among the various techniques is noteworthy. Accordingly, we systematically reviewed the development and limitations of novel TOO identification methods, compared their pros and cons and assessed their potential clinical usefulness. Our study may help patients shift from empirical to customized care and improve their prognoses | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cancer of unknown primary (CUP) | |
| 650 | 4 | |a gene expression profiling | |
| 650 | 4 | |a image omics | |
| 650 | 4 | |a liquid biopsy | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a tissue of origin (TOO) | |
| 700 | 1 | |a Wu, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yiran |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Hongxia |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Junjie |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Bang |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Mingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiaolu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Xinhui |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Xuanwen |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yifei |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Nong |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Haiping |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yongfeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Briefings in bioinformatics |d 2000 |g 25(2024), 2 vom: 22. Jan. |w (DE-627)NLM11366883X |x 1477-4054 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:2 |g day:22 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/bib/bbae028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 2 |b 22 |c 01 | ||